Evidence map›Paper›PMID 35197570›Full record

ArticleOncogene2022

A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway.

Siqi Wu, Binbin Guo, Liyuan Zhang, Xun Zhu, Peipei Zhao, Jieqiong Deng, Jian Zheng, Fang Li, Yirong Wang, Shenghua Zhang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. The hidden players: LncRNA-Encoded micropeptides in cancer hallmarks.Cellular and molecular life sciences : CMLS · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Regulation of Metastasis and Growth of Colorectal CancerRecent patents on anti-cancer drug discovery · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Siqi Wu *Department of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Binbin Guo *Department of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Liyuan Zhang *Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, China.
Xun Zhu *Department of General Surgery, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, China.
Peipei ZhaoDepartment of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, China.
Jieqiong DengDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Jian ZhengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.ORCID http://orcid.org/0000-0001-9831-7038
Fang LiDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Yirong WangDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Shenghua ZhangDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Zheng ZhangDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China.
Jiachun LuThe Institute for Chemical Carcinogenesis, The First Affiliated Hospital, The School of Public Health, Guangzhou Medical University, Guangzhou, 510182, China.ORCID http://orcid.org/0000-0002-9999-7220
Yifeng ZhouDepartment of Genetics, Medical College of Soochow University, Suzhou, 215123, China. zhouyifeng@suda.edu.cn.ORCID http://orcid.org/0000-0003-1847-7985
Soochow University · CNSun Yat-sen University · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with a poor prognosis. To date, the mechanism of TNBC's aggressive phenotype is still unclear. Based on metabolome analysis, we found that glutamine (Gln) metabolism plays a key role in the difference between TNBC and non-TNBC. We identified a 21-amino-acid survival-associated micropeptide XBP1SBM, encoded by the lncRNA MLLT4-AS1, which was upregulated in TNBC tissues and Gln-deprived TNBC cell lines. We showed that XBP1SBM expression was upregulated by Gln-deprivation-induced XBP1s transcriptional promotion, and in turn retained XBP1s in the nuclear to enhance the expression of VEGF. Using human endothelial cells, mouse xenograft models and mouse spontaneous BC models, we found that XBP1SBM improved Gln levels and promoted angiogenesis and metastasis in TNBC. Our study showed that a TNBC-specific nutrient deficiency adaption results in aggressive TNBC, and this mechanism provides a novel potential prognostic biomarker and therapeutic target in TNBC.

Indexed as

RNA, Long NoncodingTriple Negative Breast NeoplasmsAnimalsCell Line, TumorEndothelial CellsGene Expression Regulation, NeoplasticHumansMiceNeovascularization, PathologicX-Box Binding Protein 1RNA, Long NoncodingX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID35197570
OpenAlexW4213427065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.